

February 11, 2020

Corporate Relationship Department,
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400 001.

Through: BSE Listing Centre

Scrip Code: 540 788

Subject: Newspaper advertisement pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.

Dear Sir,

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, we are enclosing herewith the copy of Newspaper advertisement of the Standalone unaudited Financial Results for the quarter ended 31st December, 2019 published in Business Standard (English Language) and Mumbai Lakshadeep (Marathi Language) on February 05, 2020 for your reference and record.

Kindly take the note of the same.

Thanking you.

Yours faithfully,


For Aspira Pathlab & Diagnostics Limited


Mamta

Mamta Mav
Company Secretary



Encl: as above

 ASPIRA PATHLAB & DIAGNOSTICS LIMITED CIN: - L85100MH1973PLC289209 Reg. Office : Flat No.2, R.D.Shah Building, Shradhanand Road, Opp. Railway Station, Ghatkopar (W.), Mumbai -400086 email ID: info@aspiradiagnostics.com ; website: www.aspiradiagnostics.com				
Extracts of unaudited Financial Results for the Quarter and Nine Months ended December 31, 2019				
(Rupees in Lakhs)				
Sr. No	Particulars	Quarter Ended 31/12/2019 (Unaudited)	Nine Months ended 31/12/2019 (Unaudited)	Quarter Ended 31/12/2018 (Unaudited)
1.	Total income from operations	221.98	644.84	208.06
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and /or Extraordinary items#)	(101.91)	(292.67)	(123.24)
3.	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	(101.91)	(292.67)	(123.24)
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	(101.91)	(292.67)	(123.24)
5.	Total Comprehensive Income for the period (Comprising profit/(loss) for the period(after tax) and other Comprehensive Income(after tax)	(101.91)	(292.67)	(123.24)
6.	Equity Share Capital	929.30	929.30	819.30
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	-	-	-
8.	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations)-			
	Basic:	(1.10)	(3.15)	(1.50)
	Diluted:	(1.18)	(3.51)	(1.50)
Note: a. The above is an extract of the detailed format of Unaudited Financial Results for the Quarter ended December 31, 2019, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Nine Months ended December 31, 2019 is available on the websites of the Stock Exchange(s) and the company's website: - www.aspiradiagnostics.com . b. The above result has been reviewed by the Audit Committee and approved by Board of Directors at their meeting held on February 4, 2020				
For and on behalf of the Board For Aspira Pathlab & Diagnostics Limited Sd/- Dr. Pankaj Shah (Managing Director) DIN: - 02836324				
Place: - Mumbai Date: - February 4, 2020				

 ASPIRA PATHLAB & DIAGNOSTICS LIMITED CIN: - L85100MH1973PLC289209 Reg. Office : Flat No.2, R.D.Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W.), Mumbai -400086 email ID: info@aspiradiagnostics.com ; website: www.aspiradiagnostics.com				
Extracts of unaudited Financial Results for the Quarter and Nine Months ended December 31, 2019				
(Rupees in Lakhs)				
Sr. No	Particulars	Quarter Ended 31/12/2019 (Unaudited)	Nine Months ended 31/12/2019 (Unaudited)	Quarter Ended 31/12/2018 (Unaudited)
1.	Total income from operations	221.98	644.84	208.06
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and /or Extraordinary items#)	(101.91)	(292.67)	(123.24)
3.	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items#)	(101.91)	(292.67)	(123.24)
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items#)	(101.91)	(292.67)	(123.24)
5.	Total Comprehensive Income for the period (Comprising profit/(loss) for the period(after tax) and other Comprehensive Income(after tax))	(101.91)	(292.67)	(123.24)
6.	Equity Share Capital	929.30	929.30	819.30
7.	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year	-	-	-
8.	Earnings Per Share (of ₹ 10/- each) (for continuing and discontinued operations)-			
	Basic:	(1.10)	(3.15)	(1.50)
	Diluted:	(1.18)	(3.51)	(1.50)
Note: a. The above is an extract of the detailed format of Unaudited Financial Results for the Quarter ended December 31, 2019, filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the Quarter and Nine Months ended December 31, 2019 is available on the websites of the Stock Exchange(s) and the company's website: - www.aspiradiagnostics.com . b. The above result has been reviewed by the Audit Committee and approved by Board of Directors at their meeting held on February 4, 2020				
For and on behalf of the Board For Aspira Pathlab & Diagnostics Limited Sd/- Dr. Pankaj Shah (Managing Director) DIN: - 02836324				
Place: - Mumbai Date: - February 4, 2020				